Page values for "Treximet"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Sumatriptan / Naproxen
brand	`String`	Treximet
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Triptans\|Triptan (5-HT1B/1D agonist)]] • [[:Category:NSAIDs\|NSAID (naproxen)]] • [[:Category:Antimigraine_agents\|Antimigraine agent]] • [[:Category:Fixed-dose_combinations\|Fixed-dose combination]]
mechanism	`String`	'"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'.
uses	`String`	'"`UNIQ--vote-000015D0-QINU`"'
starting_dose	`String`	1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours
preparations	`String`	85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric)
fda_max	`String`	2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Headache relief at 30-60 minutes
duration	`String`	4-8 hours
halflife	`String`	Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"'
bioavailability	`String`	Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"'
pregnancy	`String`	Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"'